key: cord-0902948-hsbjbwpa
authors: Dongyuan, Wang; Zigang, Li; Yihui, Liu
title: An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics
date: 2020-07-13
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2020.07.004
sha: 1850afda054910928484600c9c55ae89b794cdd9
doc_id: 902948
cord_uid: hsbjbwpa

Since a novel coronavirus pneumonia outbreak in late December 2019, coronavirus disease -19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health event. No specific antivirals are currently available for COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The treatments for COVID-19 are mainly based on the experiences of similar virus such SARS-CoV, MERS-CoV, HIV and influenza viruses. Scientists have taken great efforts to investigate the effective methods for the treatment of COVID-19. Up to now, there are over 1000 clinical studies for COVID-19 all over the world. In this article, we reviewed the current options for COVID-19 therapy including small molecules such as Remdesivir, Favipiravir, Lopinavir/Ritonavir etc, peptide inhibitors of ACE2, Traditional Chinese Medicines and Biologics such as SARS-CoV-2-specific neutralizing antibodies, mesenchymal stem cells and vaccines etc. Meanwhile, we systematically reviewed their clinical safety, clinical applications and progress of antiviral researches. The therapeutic effect of these antiviral drugs is summarized and compared, hoping to provide some ideas for clinical options of COVID-19 treatment and also provide experiences for the life-threatening virus diseases in the future.

RNA to generate new coronavirus particles, which are secreted to extracellular environment through Golgi apparatus and infect new cells [7] .

With a better understanding of the structure, the infection mechanisms of SARS-CoV-2 and the clinical symptoms of COVID-19 patients, many drugs had been used for the clinical practice of COVID-19. Up to now, the therapeutic options for COVID- 19 can be classified into small molecules, peptide inhibitors, Traditional Chinese Medicines and biologics summarized in Table 1 . In late May, 2020, over 1600 clinical trials have been registered to find the effective treatments for COVID-19 from clinical trial registry platforms (http://clinicaltrials.gov/ and http://www.chictr.org.cn/). The most widely used therapeutic drugs include Abidol, Ribavirin, Favipiravir, Interferonα, Chloroquine/Hydroxychloroquine, Kaletra(Lopinavir/Ritonavir), Remdesivir (GS-5734), SARS-CoV-2-specific neutralizing antibodies and so on. Besides, the newly discovered small drugs, peptides and vaccine are also under pre-clinical or clinical researches. In this paper, we systematically introduced the safety, clinical efficacy, and the progress of antiviral researches of these drugs, hoping to provide some ideas for the therapeutic options of COVID-19 worldwide and better understand the antiviral strategies prepared for the life-threaten virus diseases in the future. J o u r n a l P r e -p r o o f 

3.1 Nucleoside analogues

Remdesivir (GS-5734) is a novel prodrug of an adenosine analogue and effective against a broad spectrum of human and pre-epidemic zoonotic CoVs [15] . Remdesivir can be triphosphorylated in cells and act as a substrate of virus RNA-dependent RNA polymerase (RdRp) and penetrate into the virus newly synthesized RNA strand, thus interrupting the synthesis of the virus genome [12] .

In the phase I clinical trial of Remdesivir, 3-225 mg intravenous injection of single dose hill climb test was conducted. The subjects showed good tolerance, and all the adverse reactions were grade 1 or grade 2 with aspartic transaminase (AST) or alamine aminotransferase (ALT) increasing, but no abnormality in total bilirubin, alkaline phosphatase (ALP) or albumin, and no effect on renal function [16] . According to a recently Randomised Clinical Trial (RCT) of COVID-19, 66% (102/155)adverse events of Remdesivir treatment were observed compared to the 64%(50/78) in placebo treatment [17] .

Remdesivir has not yet been approved for antiviral therapy and is currently used days [17] . The outcomes of another multicenter RCT of Remdesivir in COVID-19

patients has present a significant shorten in duration of discharge from hospital without significant difference in mortality [17] . According to these studies, we still do not know the benefit or harm of Remdesivir treatment in severe COVID-19 patients. However, further studies of Remdesivir in patients with COVID-19 in higher dosage or combination with other antivirals agents might help us to better understand its potential mechanism and clinical efficacy.

Ribavirin is a guanosine analogue with broad-spectrum antiviral activity against RNA viruses. The antiviral mechanisms of Ribavirin includes fatal mutagenesis, specific or non-specific chain termination and inhibition of nucleotide biosynthesis etc [23, 24] .

The reproductive toxicity and the hemolytic anemia is the most serious side effects of Ribavirin. Some cohort studies of Ribavirin showed that patients on therapy with loading dose of Ribavirin experience significant toxic and side effects, such as hemolytic anemia [25] . In another retrospective study, among the 126 patients who received loading dose of Ribavirin(2,000mg) treatment, the mainly adverse drug reactions included hemolytic bleeding, bradyarrhythmia(14%) and elevated transaminase(40%) [26] . Thus, the dose of Ribavirin need to be carefully adjusted to treat patients with COVID-19.

Ribavirin is only approved by FDA for Hepatitis C, human respiratory syncytial virus (RSV) and some hemorrhagic fevers in combination with pegylated interferon. In

China, Ribavirin is used for the patients with COVID-19, which is mentioned in"Novel

by the Chinese government [27] . It is recommended to use Ribavirin in combination with Interferon or Lopinavir/Ritonavir, the dosage for adults is 500 mg per time, 2~3 times per day by intravenous infusion, and the course of treatment is no longer than 10 days.

The clinical studies in Hong Kong have shown that Ribavirin couldn't improve clinical outcome of patients with SARS-CoV [28] . In 20 MERS-CoV infected patients, a combination treatment of Ribavirin and IFN-α showed significantly improved survival at 14 days but not at 28 days [29] . Although Ribavirin has shown a certain effect on MERS-CoV, it is still controversial [30, 31] . In China, Ribavirin was chosen J o u r n a l P r e -p r o o f for patients with COVID-19 in combination with IFN or Lopinavir/Ritonavir according to the clinical guidelines [27] . A clinical trial showed the significantly antiviral effect of combination treatment of Ribavirin and IFN-α on patients with MERS-CoV [32] .

But the adverse reaction of decreasing hemoglobin in infected patients reduces its potential antiviral agent against COVID-19. Take consideration of limited efficacy of Ribavirin against coronaviruses and toxicity in vivo, some medical team stop Ribavirin treatment and related studies.

Favipiravir is a nucleoside analogue that can be triphosphorylated in cells and act as a substrate of virus RNA-dependent RNA polymerase (RdRp) [33] .

The most serious side effect of Favipiravir is teratogenicity. In the phase III of a Japanese and international multi-center clinical trial with 501 patients, the main adverse reactions including rising uric acid(24 cases, 4.79%), diarrhea(24 cases, 4.79%), neutropenia(9 cases, 1.80%), increased AST(9 cases, 1.80%) and increased ALT(8 cases, 1.60%) [34] . In a randomized clinical trial of Favipiravir with 240 patients with COVID-19, the most common adverse events were liver enzyme abnormalities, psychiatric, gastrointestinal symptoms and serum uric acid elevations.0001) [35] . The overall adverse reactions were mild symptoms, but pregnant woman should not be treated with Favipiravir.

Favipiravir is approved in Japan for treatment of new or recurrent influenza. 

In 2014, Favipiravir was urgently used to treat Ebola virus and achieved good results [36, 37] . In 2020, Favipiravir showed cytotoxicity in Vero E6 cells infected with SARS-CoV-2 at EC50 of 61.88μM [20] . 

Kaletra is a compound preparation with two specifications (Lopinavir/Ritonavir).

Lopinavir is an HIV protease inhibitor, which can influence the formation of matured virus particles and weaken the infectivity of the virus [39] . Lopinavir has poor bioavailability and short half-life time. Ritonavir is a cytochrome CYP3A4 enzyme inhibitor, which can inhibit the metabolism of Lopinavir. The combined treatment of Lopinavir and Ritonavir can significantly enhance the bioavailability of Lopinavir and improve its antiviral effect in vivo [13] .

A retrospective analysis with Kaletra for 60 weeks showed that diarrhea, nausea and vomiting are the main adverse reactions [40] . A retrospective study with 417 patients with COVID-19 revealed that the use of Lopinavir/Ritonavir lead to increased odds of liver injury (OR from 4.44 to 5.03, both p <0.01) [41] . Another study revealed that Lopinavir/Ritonavir has an uncertain antiviral effect and even some potentially severe side effects in solid organ transplant recipients with COVID-19 [42] .

Lopinavir/Ritonavir have a synergistic effect on tacrolimus, resulting in higher trough blood concentrations of tacrolimus and cause severe liver and kidney dysfunction and also greatly damage the function of the immune system [43] . 

As early as 2003, Kaletra was considered as a clinical option for the treatment of SARS, and it indeed showed antiviral effect on SARS both in tissues and patients [44] .

One clinical research in Hong Kong showed that Kaletra reduced the mortality rate of SARS-CoV from 15.6% to 2.3%, but it mainly exhibited good effect on patients with mild symptoms [45] . [49] . It seems that the combination of Lopinavir-Ritonavir with interferon β-1b, and Ribavirin or other drugs could have better effect than Lopinavir-Ritonavir alone.

Chloroquine (CQ) is a weak base, which can enter cells and accumulate in lysosome, trans Golgi network and other acidic organelles through protonation, so as to increase the pH value and destroy the structure and function of the organelles [50] . Therefore, it has a broad-spectrum antiviral effect. Hydroxychloroquine(HCQ) is a less toxic derivative of CQ which shows better clinical efficacy than CQ.

The therapeutic and toxic dose of CQ/HCQ is narrow. The main toxicological outcomes initiated by CQ and HCQ reported are related to retinopathy, neuromyopathy, and cardiomyopathy after long term use [51] . The doses used for COVID-19 are often much higher than the treatment of chronic rheumatic diseases [52] . Thus the improper or renal toxicity were seen among these patients [53] .

CQ is a widely used drug for malaria and autoimmune diseases, and it has been used for over 70 years. In 2020, CQ was recommended for the therapy of COVID-19

in the "Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme (Trial Edition Sixth)" issued by Chinese government [54] . CQ phosphate is applicable to patients aged 18 to 65. The administration mode for patients weighing over 50kg is 500mg per time, twice a day, with 7 days treatment; for those weighing no greater than 50kg is 500mg per time, twice a day for the first and second days, and 500mg per time, once a day for the third to seventh days, with 7 days treatment.

It was reported in 2004 that Chloroquine can effectively inhibit SARS coronavirus at the cellular level [55] . In 2020, Chinese researchers revealed that Chloroquine had the EC90 of 6.90μM for Vero E6 cells infected with SARS-CoV-2 [20] . A Chinese clinical trial with more than 100 COVID-19 patients found that Chloroquine had superior to the control group in reducing symptom duration, exacerbation of pneumonia including radiological improvement and promoting virus-negative seroconversion without any severe side effects [56] . Another randomized clinical trial with 81 adult patients suggested that the higher CQ dosage (600mg CQ twice daily for 10 days)

should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards [53] . A retrospective multicenter cohort study of 1438 hospitalized COVID-19 patients revealed that treatment with Hydroxychloroquine, J o u r n a l P r e -p r o o f azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality [57] . A comparative observational study with 181 COVID-19 patients suggested that Hydroxychloroquine should not be recommended to be used in COVID-19 patients who require oxygen [58] . Multinational registry analysis of CQ and HCQ for 96,032 COVID-19 patients revealed that CQ/HCQ independently associated with an increased risk of in-hospital mortality [59] . Despite many observational studies have been performed to evaluate the efficacy of CQ/HCQ, we cannot exclude the possibility of unmeasured confounding factors, making it difficult to judge the therapeutic effect of CQ/HCQ.

Interferons (IFNs) are cytokines that activate the innate immune system in response to viral infection. As a broad-spectrum antiviral drug, interferon-α (IFN-α)

itself has no direct antiviral activity, but IFN-α can provoke the synthesis of proteins that have antiviral and immunomodulatory effects. In addition, IFN can enhance the specific cytotoxic action of immune cells on target cells through immune regulation, thereby containing the invasion of virus.

In an systematic review including 8 studies(116 patients) of MERS-CoV treatment by interferon, interferon-α combined with Ribavirin caused adverse reactions: two patients had increase in pancreatic enzyme and one patient had obvious hemolysis after the treatment of interferon-α2a combined with Ribavirin [60] .

Interferon-α (IFN-α) is generally used for the treatment of malignant tumors and the prevention and treatment of virus through improving the immune function of human body [61] . The "Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme J o u r n a l P r e -p r o o f (Trial Edition Seventh)" issued by Chinese government recommended that IFN-α aerosol inhalation can be used for antiviral treatment of COVID-19 [62] . The administration mode for adults is 5 million U or equivalent dose, with 2 ml sterile water for injection, by aerosol inhalation, twice a day.

The in vitro study showed that both IFN-α and IFN-β exhibited antiviral effect on MERS-CoV and SARS-CoV [63, 64] . IFN in combination with Ribavirin showed better antiviral effect than Ribavirin alone in the renal cell line of rhesus monkey infected with MERS-CoV [65] . A clinical study compared the clinical effects of IFN-α combined with glucocorticoid and glucocorticoid alone in the treatment of SARS-CoV patients [66] . The results showed that the symptomatic relief time in pulmonary imaging of interferon-α group was shortened by 50% (P=0.001), and the oxygen saturation was significantly improved. A recent triple therapy study of interferon beta-1b, Lopinavir-Ritonavir and Ribavirin presented that remarkable differences were observed in symptom alleviation, shorten the duration of viral shedding and hospital stay in combination group [48] . However, more clinical benefits and potential anticytokine approaches of IFN are still under investigated for COVID-19.

Arbidol hydrochloride is a non-nucleoside antiviral drug. Arbidol can specifically [40] [41] [42] .

The overall adverse effect of Arbidol is mild. The commonly adverse drug reactions was nausea, abdominal discomfort, nausea with headache and leucopenia, increased AKP and increased total bilirubin. The retrospective study to evaluate the efficacy and safety of Arbidol treatment for COVID-19 patients revealed that no apparent side effect was observed during the therapy [67] .

Arbidol was first approved in Russia in 1993 for the treatment of influenza. Now,

(Trial Edition Sixth)" [54] . The administration mode for adults is 0.2g per time, 3 times a day, with the treatment lasting up to 10 days.

In 2019, Arbidol received extensive attention due to the outbreak of COVID-19.

Early studies have shown that Arbidol has an effect of inhibiting the early replication of SARS virus in vitro [68] . Recent study reported that Arbidol efficiently inhibited SARS-CoV-2 infection in vitro with EC50 of 4.11μM which suggested Arbidol might have potential for the treatment of COVID-19 patients [69] . A retrospective study was performed to evaluate the antiviral effects and safety of Lopinavir/Ritonavir and Arbidol in 50 COVID-19 patients, which indicated that Arbidol group had a shorter viral load compared to those in the Lopinavir/Ritonavir group (P<0.01) and may have J o u r n a l P r e -p r o o f better antiviral effect than Lopinavir/Ritonavir [67] . Another retrospective study with 81 COVID-19 patients revealed that Arbidol group had longer hospital stay than the control group, and the median time for turning negative was similar with the control, which suggested that Arbidol might not improve the prognosis or accelerate SARS-CoV-2 clearance [70] . However, one research with 69 enrolled COVID-19 patients revealed that Arbidol had tendency to improve the discharging rate and decrease the mortality rate [71] .

Lianhuaqingwen (LH) is mainly used to treat influenza which showed antiviral activity and clinical improvement on series of influenza viruses. The relieved symptoms include fever or hyperpyrexia, aversion to cold, muscular soreness, nasal obstruction, running nose, cough, headache and so on. The recommended dosage for adults is 4 capsules per time (0.35g power/capsule), three times a day.

Since the outbreak of COVID-19 pandemic, Chinese doctors have used LH to treat patients with common and severe COVID-19. As a potential treatment agent against SARS-CoV-2, LH showed excellent antiviral and antiinflammatory activity on novel coronavirus in vitro [72] . Another human RCT presented that standard antiviral therapy combined with LH can significantly improve the symptoms of COVID-19, such as fever, cough and fatigue in most of common COVID-19 patients, relieve the pneumonia symptoms, and significantly shorten the duration of pneumonia symptoms without observed serious adverse events [73] . This provides a preliminary evidence of the antiviral activity of LH for COVID-19. LH and other traditional Chinese medicines have also played a positive role in antiviral efficacy against SARS -CoV-2 during pandemic.

J o u r n a l P r e -p r o o f

Biologics have attracted much attention during the epidemic outbreak worldwide, including mesenchymal stem cells, SARS-CoV-2-specific neutralizing antibodies and vaccines.

Convalescent plasma may contain the human antibody specific for SARS-CoV-2 produced by whom recovered from SARS-CoV-2 infection. The concept of convalescent serum therapy is based on the human immunity, which is obtained from a patient who has survived a previous infection and developed humoral immunity against the pathogen responsible for the disease [74] . Convalescent plasma could be a valid option for several infections when a specific treatment is not available.

At present, convalescent blood products are mainly used for acute and severe virus infections without available vaccine or specific therapy, such as SARS-CoV, MERS-CoV, Ebola etc. The "Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme (Trial Edition Seventh)" recommended convalescent plasma therapy for serious and extreme cases of COVID-19 [62] .

In 2015, a systematic analysis of the treatment of SARS-CoV with convalescent plasma and hepatitis B immune globulin was reported [75] .

Evidences continuously proved that convalescent blood products can reduce the total mortality of SARS-CoV, especially in the early stage of symptoms. The clinical trials of convalescent plasma are undergoing for the treatment of patients with severe COVID-19. A case series study of convalescent plasma showed that the clinical symptoms were significantly relieved within 3 days of treatment, suggesting that the plasma was effective in treating severe COVID-19 patients J o u r n a l P r e -p r o o f [76] . The convalescent plasma is considered to have possible source of specific antibodies for pathogen. However, it can also be challenging due to the limited serum with sufficiently high antibody and small sample size. Convalescent plasma therapy could be a valid option for severe COVID-19 patients when a specific treatment is not available.

Mesenchymal stem cells (MSCs) are multipotent cells isolated from diverse mesenchymal tissues such as bone marrow, umbilical cord, adipose tissue [77] .

MSCs can enlarge the proportion of regulatory T cells and decrease proinflammatory factors such as IL-6 and TNF-α, which have a great potential to improve the outcome of COVID-19 patients [78] . The immunomodulating effects of MSCs have been proven on avian influenza viruses [79] . 

Besides the drugs introduced above, there are many promising drugs registered with the intention of discovering effective treatments. 

The drugs such as small inhibitors, ACE2 peptide inhibitors or vaccines specific for SARS-CoV-2 are new hope for the treatment of COVID-19. We believe that the numerous experiences reviewed in this paper will promote the development of effective drugs for COVID-19 patients.

No potential conflict of interest was reported by the author(s).

Real-time big data reporting of novel coronavirus pneumonia outbreaks from Baidu

Coronaviruses -drug discovery and therapeutic options

Coronavirus diversity, phylogeny and interspecies jumping

Cultivation of the virus of infectious bronchitis of chickens in embryonated chicken eggs

A Novel Coronavirus from Patients with Pneumonia in China

Recent Aspects on the Pathogenesis Mechanism, Animal Models and Novel Therapeutic Interventions for Middle East Respiratory Syndrome Coronavirus Infections

Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses

Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Identification of ferret ACE2 and its receptor function for SARS-coronavirus

Structure of MERS-CoV spike receptorbinding domain complexed with human receptor DPP4

Proteolytic activation of the SARScoronavirus spike protein: cutting enzymes at the cutting edge of antiviral research

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Controlled Trial of Ebola Virus Disease Therapeutics

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

First Case of 2019 Novel Coronavirus in the United States

Compassionate Use of Remdesivir in Covid-19. Reply

Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis

Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action

Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

Guidelines for Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme(Trial Edition Fifth)

Severe acute respiratory syndrome (SARS) in Hong Kong: patients' experiences

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

Al Mutairy E. Ribavirin and interferon-alpha2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases

Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea

Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever

Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model

Experimental Treatment with Favipiravir for

COVID-19: An Open-Label Control Study. Engineering (Beijing) 2020

Lopinavir/ritonavir: a review of its use in the management of HIV infection

Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections

COVID-19: Abnormal liver function tests

Coronavirus disease 2019 and transplantation: A view from the inside

Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Effects of chloroquine on viral infections: an old drug against today's diseases?

Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review

Of chloroquine and COVID-19

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Guidelines for Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme (Trial Edition Sixth)

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and metaanalysis

High efficiency targeting of IFN-alpha activity: possible applications in fighting tumours and infections

Guidelines for Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme

Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma)

MERScoronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment

Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study

Clinical Features of 69 Cases with Coronavirus Disease

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial

Convalescent plasma: new evidence for an old therapeutic tool?

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory metaanalysis

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Concise review: the surface markers and identity of human mesenchymal stem cells

Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia

Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice

Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients

Preliminary evaluation of the safety and efficacy of oral human antimicrobial peptide LL-37 in the treatment of patients of COVID-19, a small-scale, single-arm, exploratory safety study

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan

Dongyuan Wang and Yihui Liu drafted the manuscript; Zigang Li contributed to conception and design of the manuscript; all authors provided critical review of the manuscript and agree to be accountable for its contents.